Sirolimus Drug Profile

What is Sirolimus?

Sirolimus is an immunosuppressive medication belonging to a class of drugs called mTOR inhibitors. It is primarily used to prevent organ rejection in kidney transplant recipients and has additional applications in treating certain vascular conditions. The drug works by suppressing the immune system’s ability to attack transplanted organs or tissues.

Uses

• Kidney transplant rejection prevention: The primary FDA-approved use is preventing rejection in patients who have received kidney transplants, typically used in combination with other immunosuppressive drugs.
• Lymphangioleiomyomatosis (LAM): Treatment of this rare lung disease that primarily affects women, helping to preserve lung function and reduce symptoms.
• Drug-eluting stents: Coated on coronary stents to prevent restenosis (re-narrowing of arteries) after cardiac procedures.
• Tuberous sclerosis complex: Treatment of certain manifestations including renal angiomyolipomas and subependymal giant cell astrocytomas.
• Off-label autoimmune conditions: Sometimes used for severe autoimmune diseases when other treatments have failed, though this requires careful specialist supervision.

How it works

Sirolimus inhibits the mechanistic target of rapamycin (mTOR), a protein that plays a crucial role in cell growth, proliferation, and immune responses. By blocking mTOR signaling pathways, the drug suppresses T-cell activation and proliferation, which are key components of the immune system’s rejection response. This mechanism also affects cellular processes involved in abnormal tissue growth, making it useful for conditions beyond transplant medicine.

Side effects

Common side effects:

• Mouth ulcers and oral inflammation
• Diarrhea and abdominal pain
• High cholesterol and triglycerides
• Swelling of hands, feet, or ankles
• Acne and skin rash
• High blood pressure
• Joint pain
• Headache and dizziness

Serious side effects requiring immediate medical attention:

Submit Your Paper

• Increased susceptibility to infections due to immune suppression
• Increased risk of certain cancers, particularly skin cancer and lymphoma
• Lung inflammation (pneumonitis) causing breathing difficulties
• Severe kidney problems
• Poor wound healing and tissue repair

Warnings and precautions

• Pregnancy and breastfeeding: Sirolimus can cause fetal harm and should not be used during pregnancy. Women of childbearing age should use effective contraception during treatment and for 12 weeks after discontinuation.
• Infection monitoring: Patients require regular monitoring for signs of infection, as the drug significantly suppresses immune function and increases vulnerability to bacterial, viral, and fungal infections.
• Kidney and liver function: Regular blood tests are essential to monitor kidney and liver function, as sirolimus can affect both organs and requires dose adjustments in patients with impaired function.
• Surgical considerations: The drug should be used with caution before and after surgery due to impaired wound healing, and temporary discontinuation may be necessary.
• Skin cancer screening: Patients should undergo regular skin examinations and limit sun exposure, as immunosuppression increases skin cancer risk significantly.

Interactions

• CYP3A4 inhibitors (ketoconazole, clarithromycin, grapefruit juice): Increase sirolimus blood levels, potentially causing toxicity and requiring dose reduction.
• CYP3A4 inducers (rifampin, phenytoin, St. John’s wort): Decrease sirolimus effectiveness by reducing blood levels, may require dose increases.
• ACE inhibitors and ARBs: May increase risk of angioedema, particularly in transplant patients taking multiple immunosuppressive drugs.
• Live vaccines: Should be avoided due to increased infection risk from the weakened immune system.
• Cyclosporine: Increases sirolimus blood levels and toxicity; timing of administration must be carefully managed.
• HMG-CoA reductase inhibitors (statins): Combined use may increase risk of muscle toxicity (rhabdomyolysis).
• Diltiazem and verapamil: Calcium channel blockers that can significantly increase sirolimus blood concentrations.
• Tacrolimus: Concurrent use may increase nephrotoxicity risk and requires careful monitoring of kidney function.

Check interactions with the GMJ Interaction Checker

Dosage

For kidney transplant patients, the typical initial dose is 6 mg taken orally as a loading dose, followed by 2 mg daily. Maintenance doses are typically 1-5 mg daily, adjusted based on blood levels and clinical response. For LAM treatment, the usual dose is 2 mg daily. Dosing must be individualized based on therapeutic drug monitoring, with target blood levels typically maintained between 5-15 ng/mL depending on the indication. All dosing decisions should be made by a healthcare provider experienced in immunosuppressive therapy, with regular blood level monitoring to ensure safety and effectiveness.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).